October 3, 2019 10:21 AM EDTUpdated 05:18 PM
People

Piv­otal fail­ure trig­gers job cuts at San Diego-based Toca­gen

Natalie Grover

Reporter

Toca­gen is cir­cling the drain, fol­low­ing the crush­ing late-stage fail­ure of its ex­per­i­men­tal brain can­cer ther­a­py last month. On Thurs­day, the San Diego-based com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

A service from the Financial Times